Journal Watch · Frontiers in Immunology · 2026
Development and validation of an interpretable machine learning model identify the lactylation-related protein SUSD3 as a prognostic and therapeutic biomarker for breast cancer.
This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
TL;DR
This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
Key findings
- It is expected to become a potential therapeutic target and a diagnostic marker for breast cancer.
- This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
What they did
This raises questions about whether it serves as a primary driver or a secondary regulator during cancer development, as well as its influence on the tumor immune microenvironment and prognostic implications.<h4>Methods</h4>This study investigates the clinical relevance of lactylation-related genes (LRGs) in breast cancer through a comprehensive analysis of extensive genomic datasets, including single-cell RNA sequencing, bulk transcriptomic data, and spatial transcriptomics from established public databases such as TISCH, TCGA, and GEO.<h4>Results</h4>By using a combination of multiple machine-learning algorithms, we developed an effective lactylation-related signature that correlates with immune cell infiltration, chemokine expression, and tumor mutation burden. This signature proved useful in identifying breast cancer patients likely to respond to immunotherapy. Finally, we experimentally validated the quantified expression levels of hub genes in human breast samples and demonstrated the role of SUSD3.<h4>Conclusion</h4>These findings indicate that our lactylation risk model can be used to predict the malignant progression and immune evasion of breast cancer.
Full abstract (original)
Background: <h4>Background</h4>Breast cancer is one of the most prevalent malignancies and a leading cause of cancer-related mortality among women. Lactylation, a recently recognized post-translational modification, has emerged as a significant factor in tumor biology, with increasing evidence linking it to cancer progression and immune modulation. However, the role of lactylation in tumorigenesis remains ambiguous.
What they did: This raises questions about whether it serves as a primary driver or a secondary regulator during cancer development, as well as its influence on the tumor immune microenvironment and prognostic implications.<h4>Methods</h4>This study investigates the clinical relevance of lactylation-related genes (LRGs) in breast cancer through a comprehensive analysis of extensive genomic datasets, including single-cell RNA sequencing, bulk transcriptomic data, and spatial transcriptomics from established public databases such as TISCH, TCGA, and GEO.<h4>Results</h4>By using a combination of multiple machine-learning algorithms, we developed an effective lactylation-related signature that correlates with immune cell infiltration, chemokine expression, and tumor mutation burden. This signature proved useful in identifying breast cancer patients likely to respond to immunotherapy. Finally, we experimentally validated the quantified expression levels of hub genes in human breast samples and demonstrated the role of SUSD3.<h4>Conclusion</h4>These findings indicate that our lactylation risk model can be used to predict the malignant progression and immune evasion of breast cancer.
Results & conclusions: It is expected to become a potential therapeutic target and a diagnostic marker for breast cancer. This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1701978 · PubMed 41676158.
Why it matters for pharma & biotech
- Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: AI in drug discovery / diagnostics
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
What type of study is this?
It is a genomics / omics study, published in Frontiers in Immunology in 2026. This raises questions about whether it serves as a primary driver or a secondary regulator during cancer development, as well as its influence on the tumor immune microenvironment and prognostic implications.<h4>Methods</h4>This study investigates the clinical relevance of lactylation-related genes (LRGs) in breast cancer through a comprehensive analysis of extensive genomic datasets, including single-cell RNA sequencing, bulk transcriptomic data, and spatial transcriptomics from established public databases such as TISCH, TCGA, and GEO.<h4>Results</h4>By using a combination of multiple machine-learning algorithms, we developed an effective lactylation-related signature that correlates with immune cell infiltration, chemokine expression, and tumor mutation burden.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1701978. PubMed ID: 41676158. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/development-and-validation-of-an-interpretable-machine-learning-model-id-701978/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides